Headline: The Abortion Aftermarket: An Investigative Report Dateline: Washington DC, April 19, 2009 Byline: Linda Royall
The Abortion Aftermarket The Global Baby Body Parts Industry Operating Within the Nations' Capital
At the end of each day, an innocuous brown van pulls up to the back of the abortion clinic in the evening hours. Carrying an orange plastic cooler, the driver enters through an unlocked back door. He exits, only moments later, cooler full, with some bags containing intact mid-term fetuses and several bags of early term abortion remains.
According to sources inside the reproductive health industry, the courier makes the rounds of a dozen or so clinics in the D.C. metropolitan area throughout the week, basing his pick up days on the facilities’ pregnancy termination schedules. Another driver covers the ten or so clinics in Northern areas of Maryland and Virginia. Each day’s manifest ends with the cargo being taken to one of several possible destinations – embryonic stem cell and fetal tissue transplantation research laboratories located along the Rockville Pike medical technology corridor. (1)
This scene is repeated frequently throughout the U.S., mostly in metropolitan areas of states that have no ban on the contracting for and transporting of aborted fetuses for medical research. (2) The remains of many of the million plus elective abortions (3) that take place in 2009 will most likely end up as raw material for the multi-billion dollar “life science” industry or as research product for federally funded National Institute of Health (NIH) biomedical experimentation projects. These type organizations are clustered primarily within the eight states that have liberal abortion and fetal brokering laws. (4)
Research utilizing embryonic and fetal tissue has been on going in the U.S. for more than fifty years. Legislation regarding fetal tissue research historically dovetails with ancillary laws on abortion.
Timeline
In the 1950’s fetal tissue from miscarried pregnancies was used to develop polio and rubella vaccines. Fetal tissue research, though ongoing, was relatively obscure until the mid-1970’s. (5)
Research performed on fetuses obtained from elective abortions came under close scrutiny after the 1973 U.S. Supreme Court decision in Roe v. Wade, 410 U.S. 113, 93 S. Ct. 705, 35 L. Ed. 2d 147, which protects the right of a woman to have an abortion in the first and second trimesters of pregnancy. (6)
In 1974, the National Research Act (Pub. L. No. 93-348) created a national commission to oversee research projects involving fetuses. This body formulated research guidelines and placed restrictions on what types of fetal research could receive federal funding. (7)
In 1988, NIH scientists requested approval from the Department of Health and Human Services (HHS) to begin transplantation experiments using fetal brain tissue. HHS imposed a temporary hold on federal funds for research using fetal tissue due to the concerns of President Ronald Reagan about the link between fetal tissue research and elective abortion. (8)
In 1989 a twenty-one-member NIH panel approved the use of human fetal tissue for transplantation, contending that such research would not cause more abortions. Even so, Secretary Louis W. Sullivan, of the HHS, extended the moratorium indefinitely. (8)
In 1992, the U.S. Public Health Service/NIH was mandated to by Presidential order to set up clinical laboratories for the purpose of facilitating research projects using embryonic and fetal tissue. In accordance with the directive PHS/NIH awarded five grants, to establish fetal tissue banks to provide human embryos and fetal tissue for research and experimental transplantation therapy. The order mandated the fetal tissue could only be derived from spontaneous abortions or ecoptic pregnancies. (9)
In 1993, President Bill Clinton ordered the end of the moratorium on federal funds for research using fetal tissue (58 Fed. Reg. 7457). Later in 1993, Congress passed the NIH Revitalization Act, which permits the use of fetal tissue from any type of abortion for biomedical research, with stipulations regarding “reasonable fees for obtaining and delivery of tissue”. (10)
In 1999, a Congressional hearing was called regarding the questionable practices of several companies involved in fetal tissue brokerage. A whistleblower that worked for one of the suppliers testified before congress and the industry was exposed to public scrutiny through coverage by major media outlets. (11)
HR3980 “Human Fetal Tissue Reporting and Disclosure Act of 2000'' was enacted by Congress to require that all details of trafficking and use of fetal tissue be reported to the Secretary of HHS. (12)
In 2001, President George W. Bush issued a Statement limiting Federal funding for research involving human embryonic stem cells. (13)
In 2007, Mr. Bush amended the 2002 Executive Order, bringing all embryonic and fetal tissue research under the oversight of the HHS/NIH. (13)
In March 2009, President Barack Obama issued an Executive Order to overturn the Presidential statement of August 9, 2001, limiting Federal funding for research involving human *embryonic stem cells and to revoke Executive Order 13435 of June 20, 2007, which supplemented the August 9, 2001, Presidential statement on human embryonic stem cell research. (14)
Life and Choice
*The National Institute of Health’s definition of a human embryo is “from a biological standpoint that takes into account emerging technologies in reproductive science and does not consider legal, moral, religious or social views. An embryo is created when “the first mitotic division when fertilization of a human oocyte by a human sperm is complete or any other process that initiates organized development of a biological entity with a human nuclear genome or altered human nuclear genome that has the potential to develop up to, or beyond, the stage at which the primitive streak appears, and has not yet reached 8 weeks of development since the first mitotic division.”
An unborn human is defined as an embryo from the stage of conception to eight weeks of gestation. A fetus is nine weeks and forward. The scientific community is in agreement that a human life form is generated at “first mitotic division”. However, the general consensus among secular life scientists is that a fetus does not have “viable” life until after 28 weeks of gestation.
The country has been sharply divided for decades by the topic of when viable life begins, and over what is moral and ethical concerning abortion. Pro Choice and Pro Life opponents saw away at the issues, warring back and forth over which has the correct viewpoint. The life sciences industry has interjected a new component into the controversy – the possibility of healing for such diseases as Alzheimer’s and Parkinson’s, as well as the hope that stem cell cultures may bring about cures for multitude of medical problems. The evidence that the most successful research results have been achieved using 3 ½ month human fetuses, which possess the most rapidly growing cells and adaptable cells of all pre-born humans, has enhanced the longstanding argument. (15.1)
As new biomedical discoveries unfold, the material requirements for life science research are sure to increase exponentially. The 21st century abortion aftermarket is poised to become a massive industry, and the debate between choice and life proportionally more fierce. It is a battle that has been escalating for many years.
The Early Years
The Federal government began providing Federal funding for fetal tissue research in 1992. The NIH agency was endowed to establish grants for tissue banks that “derive tissue solely from spontaneous abortions (miscarriages prior to 20 weeks of pregnancy), and ectopic pregnancies (in which a non-viable fetus develops outside the uterus)”. (9)
The five recipients of the grants were the Indiana School of Medicine, the University of Washington, the University of Minnesota, the National Disease Research Interchange in Philadelphia and the University of Utah. Ancillary tissue banks were to be located either within or nearby to the research facilities. From the onset the limiting factor was lack of access to an ample supply of healthy fetal tissue. (15)
Geneticist and pediatrician Stephen Bamforth was in charge of a fetal-tissue bank at the University of Alberta in Edmonton during the period of the ban on using fetal tissue from induced abortions in both the U.S. and Canada. In an interview with Celeste McGovern of The Canadian Citizen, Bamforth described how he and his colleagues, who were restricted to using fetuses from spontaneous abortions and ecoptic pregnancies, would “pick through the remains of miscarried 10- to 12-week-old fetuses for their hearts and eyes, from which we carefully isolated genetic material and transported it to researchers at other universities”. (16)
The difficulty in obtaining viable fetal tissue was abated in 1993 when President Bill Clinton signed the National Institutes of Health Revitalization Act of 1993, effectively lifting the moratorium on federally funded research involving transplantation of fetal tissue from either spontaneous or induced abortions. The legislation specifically allowed for "research on the transplantation of human fetal tissue for therapeutic purposes”. And it granted permission for the use of fetuses obtained through induced abortions. Thus began the harvesting of fetal tissue from abortion clinics for sale to federally funded research projects.
President Clinton’s Order opened up a huge supply line for salvaging healthy fetal tissue from the over one million induced abortion procedures that were occurring annually. The bill also provided federal funding for various projects that would later evolve into embryonic and fetal stem cell research (10) including use in both medical and industrial applications (such as food, drugs and cosmetic products).
By the late 1990’s, the sale of "services" in the procuring and processing of aborted fetal body parts became a thriving, though somewhat primitive private industry. Tissue labs forged partnerships with abortion clinics to provide fodder for both private and National Institute of Health-funded laboratories.
Alan Fantel, who operated the National Institute for Health's Laboratory for Embryology at the University of Washington at Seattle for many years, told Canadian journalist Celeste McGovern, “Our lab offers a 24-hour collection service at abortion clinics and hospitals throughout the country. (Fantel wouldn't say how many specimens his lab picked up in a week, but he acknowledged that it provided fetal remains to thousands of researchers over the years, including many Canadians). “Certainly the demand for [fetal tissue] has grown," he said. "My suspicion is there's probably a lot more to come on the private side." (16)
According to Kelly Patricia O’Meara of Insight Magazine, company pamphlets and marketing data from one such partnership, Consultative & Diagnostic Pathology, Inc. DBA: Open Lines of Pennsylvania, advertised; "Our goal to offer you and your staff the highest quality, most affordable and freshest fetal tissue prepared to your specifications and delivered in the quantities you need when you need it. Our specimens vary widely in range including but not limited to those listed below: liver, spleen, pancreas, intestines, kidney, brain, lungs and heart block, spinal column and many more with appropriate discounts that apply if specimen is significantly fragmented." And O’Meara’s interview with company owner Dr. Miles Jones revealed that he “is especially eager to attract fresh fetal tissue consumers. His fees are very attractive and lower than the industry average…the brain from an eight week fetus is only $999." (17)
How profitable was this new industry? The consulting firm of Frost and Sullivan reported that; "the worldwide market for cell lines and tissue cultures brought in nearly $428 million in corporate revenues in 1996. It (was) further predicted that between 1996 and 2003, the market would grow at an average annual rate of 13.5 percent and, by 2002, would be worth nearly $1 billion." (17)
Rapid inroads in stem cell research and fetal tissue transplantation technology during this period created an exponential growth of the fetal body part harvesting industry that far exceeded Frost and Sullivan’s projections.
Then in 1999, a Maryland man, Dean Alberty, Jr. became disgusted with his involvement in what he called “the rendering of baby bodies for parts”. Alberty had been employed as a “fetal tissue procurement technician” working for Anatomic Gift Foundation, a Maryland-based tissue procurement and processing company that had divisions in several locations throughout the U.S. AGF was also associated with a company known as Open Lines, owned by Clinical Pathologist Dr. Miles Jones.
Missy Smith, founder of the watchdog organization WAKEUP in Washington, D.C., recalls what Alberty cited to her as the incident that drove him over the edge: “Dean was a simple man who had a rather gruesome job. At that time the tissue retrieval companies would rent space in the back rooms of abortion clinics so that they could process the fetal tissue while it was still as fresh as possible. One day in a D.C. metro area abortion clinic Dean was doing his job of dissecting a just-aborted fetus. The abortion doctor came in with a square metal tub. In the tub was a set of twins, about six or so months of gestation, still moving, still alive.
Dean refused to process the fetuses, telling the doctor, ‘I will not murder those babies!’ The doctor proceeded to fill the tub with water and drown the twins. He handed the tub back to Dean, telling him he could ‘get on with his job now’.” Dean’s allegations came to the attention of Mark Crutcher, head of Life Dynamics, in Denton, Texas. Dean ultimately produced copies of over fifty orders for fetal body parts from laboratories throughout the U.S. and Canada, along with a price list from Open Lines, Inc., Dr. Jones’ human tissue processing company based in West Frankfort, Illinois. Crutcher sent the information he had gathered to all the members of Congress in late 1999.”
“The information was also leaked to media outlets such as ABC and CNN. The Orange County Register, The Washington Times, as well several Canadian publications began investigating and exposing macabre and inhumane practices that had been taking place in both clinical tissue laboratories and the backrooms of abortion clinics. Major media attention added much fuel to the fire.
ABC’s 20/20, produced a program about the fetal body parts brokering industry. The expose’ aired on March 8, 2000, creating much interest in the hearing held the following day before the Congressional Sub-Committee for Health and Environment.”
At the Congressional hearing Dean Alberty, Jr. gave very emotional testimony regarding his involvement in the fetal tissue industry:
“Upon taking the job as a fetal tissue procurement tech, I was under the impression that what I was going to do would make life better for Parkinson's patients, Alzheimer's, and cancer patients. Never was I led to believe that the tissue would be anything but helpful for those in need…What changed my mind was watching late-term abortions, seeing their eyes looking at me as I cut through their skull to extract their brain for Parkinson's and Alzheimer's patients, cutting open their chest cavity, only to see a beating heart moving ever so slowly until it stopped…Night after night in my sleep, the (drowned) twins always were there. Hearts were beating…mother’s screaming. The respect for myself was gone. How could the heroes of my life understand what I witnessed? This is why I called the FBI...and a Pro-life group. I had to tell.” (11)
The owners of the companies, The Barsdley’s of Anatomic Gift Foundation GF Maryland, and Dr. Miles Jones, the Pathologist who owned and operated Open Lines, did not appear. They were held in contempt for ignoring the subpoena that demanded their appearance before the Congressional Committee. Ultimately Congress found that the fetal tissue supply segment of the research industry dramatically lacked in legislative regulation and ethical oversight, the need of which had become necessary because of the increased demand for fetal remains. It was an industry that had quickly grown to nightmare proportions, both in size and in practice.
HR3980 “Human Fetal Tissue Reporting and Disclosure Act of 2000'' was enacted by Congress to control the sale and trafficking of fetal remains. (12) Open Lines, Inc. and many other companies like it closed up shop. Those that did remain in the tissue business managed to stay under the radar by complying with Federal requirements and through operating in states that did not have legislative oversight of the industry. The Bardsleys, owners of Anatomic Gift Foundation, ended up cooperating with the Congressional investigation, and were not cited due to their compliance. Still headquartered in Maryland, Anatomic Gift Foundation continues to operate several locations throughout the U.S.
In our interview in March of 2009, the organization’s Vice President Brenda Bardsley stated that; “Anatomic Gift Foundation has not dealt in fetal tissue for nearly ten years. We restrict our tissue donations and laboratory supply product to tissue from donated cadavers of more than 18 years of age. We never accept nor request donation of fetal, infantile or minor child remains. We do not foresee returning to that industry”.
However, Dr. Miles Jones, owner of Open Lines, is another story. An attempt at locating Jones and Dean Alberty, Jr. for interview uncovered a startling fact. They both now live in Lee’s Summit, Missouri, where Dr. Miles also owns and operates Anatomical Clinical Pathology. Neither individual could be reached by telephone. A check of the business revealed several job posting for employees for Miles new tissue laboratory.
Dr. Jones was convicted of tax fraud for the years of 2002-2003. He was sentenced to 18 months in prison and had to pay fines and make restitution of more than $100,000. Then Dr. Jones was convicted of selling prescription drugs over the Internet, and his medical license was suspended for 18 months. Now Dr. Jones is in his new tissue lab in Lee’s Summit, MO. And Dean Alberty, Jr. is quite obviously working at his side once again. (12.1)
Subsequent to the Congressional hearing in 2000, President George W. Bush repealed federal funding for stem cell research. Then in 2007 he issued an order that brought all embryonic and fetal tissue banks in the U.S. under the rule and auspices of the National Institute of Health. Mr. Bush did not seek to prevent fetal tissue transplantation and experimentation by NIH or their laboratories, nor did he outlaw the gathering and processing of fetal remains from abortion clinics for research or commercial purposes. He simply federalized it.
And his Order only stopped Federal funds for research that required new embryos to be obtained from fertility clinics. Fetal tissue transplantation and research and commercial use was not affected by this mandate. (13)
Eventually a new, more sophisticated breed of tissue laboratories emerged. The industry that began by supplying fetal tissue for NIH research has now expanded to offering human fetal product for private biomedical laboratories in the U.S. and other countries. Today, many of the companies that broker fetal tissue are commercial giants, global biomedical conglomerates that generate many billions of dollars in revenues annually.
The 21st Century Fetal Tissue Industry Today’s typical abortion aftermarket companies have morphed from backroom black market body parts brokers into boardroom-driven, high-tech NYSE listed billion dollar conglomerates. The NIH, the most-funded arm of the Federal government, is one of the largest consumers of human fetal tissue products. Some of the companies and/or their divisions began as NIH tissue laboratories, and many still supply NIH research projects. Embryonic and fetal tissue retrieval, processing and distribution now constitutes the bulk of the life science industry, supplying both for Federal and commercial customers, and is one of the fastest growing and most profitable business types in the world.
The embryonic and fetal tissue market received a real shot in the arm with President Obama’s Stimulus Plans. NIH was allocated 39.9 Billion dollars for 2009 research projects. In total NIH will receive over $800 billion for biomedical research projects from the Economic Recovery packages (18). In March 2009, NIH announced billions of dollar worth of grants for tissue repositories to acquire, process, store and supply tissue for use by Federally funded research laboratories.
The tissue banks must be located in reasonable proximity to the research facilities. There are many such laboratories already in existence, but the new mandates on embryonic and fetal stem cell research will require “many more” according to Seena Matthews of the NIH grants office. Obama’s very first presidential order was to make available billions of dollars-worth of funds to set up fetal tissue retrieval operations to insure ample supply for the burgeoning fetal remains industry.
When asked for a description of the type laboratory the NIH will be funding, Matthews referred me to NIH Letter of Solicitation Number NIH-NICHD-CDBPM-09-11which states: “The repository shall provide sufficient freezer capacity to ultimately store and maintain biologic specimens derived from approximately 4000 total human donors by the end of the five-year contract period. This estimate includes the approximate 60,000 current donor specimens from approximately 2500 donors, which will transfer with the award, as well as the projected accumulation and storage of an additional 35,000 donor specimens over the course of contract performance”.
No one inside NIH would or could answer the question; “Where will NIH funded research laboratories obtain their stock of fetuses for the repositories?”
The commercial market for end product embryonic and fetal life science products is also becoming a mega industry. The largest of these companies is Millipore, Inc. whose corporate headquarters are in Billerica, MA. The location of their huge cellular products division, 69% of which is fetal product related, is in Norcross, GA at the site the former Serological Corp., which was a 2008 acquisition of Millipore’s. Many of the smaller labs they have acquired have been absorbed into the Georgia plant over the last two years. A dozen or so tissue labs contacted pursuant to this report have all been taken over by Millipore. Some remain open in the area as Millipore branches; others were moved to Norcross, GA.
Millipore Corp. defines their operation as the world’s largest multinational life sciences company. They have 5800 employees, and 300 divisions and distributorships in 32 countries. According to their Annual Report for 2008, their focus for the coming year is to “be at the head of the line in regard to stem cell research”.
Some 39% of their several billion dollars in revenues were from “downstream life science products” (materials provided to other organizations for research). Over 60% of their assets are dedicated to the life science industry. They are an extremely profitable company, operating at a Gross Profit Marin of 52%, and according to their 2009 projections, they plan corner the market on life science biotechnological products, and become the global giant of the industry. (19 & 20).
Note: A 2024 update reveals that Millipore’s current operation is focused on “Research, Development & Production. We are a leading supplier to the global Life Science industry: solutions and services for research, development and production of biotechnology and pharmaceutical drug therapies.” Millipore is now a division of the German pharmaceutical giant Merek, that acquired many of the “life science” companies created during the fetal remains industries’ financial windfall during the Obama administration The company has two United States headquarters, in St. Louis and Burlington, MA and has operations in approximately 40 countries. In 2023 Merek companies sales of biological/bioengineered products were more than $60 billion.
Several marketing companies for the industry have emerged over the last few years as well. They act as ad agencies and provide referral services for life science products. One of the largest is Biocompare, located in South San Francisco, CA. According to Melissa Greco, the Marketing Director for the firm, they provide a free service for end-users of bioscience products. They find the leading providers in the specific genre, and then contract with them to advertise and market their products.
“If a client wants to purchase, say, a line of cells or fetal tissue for research purposes, they can search our site for the specific product. We will refer them to the best source in the industry.” They also “generate global leads for client companies, and put them in touch with the life scientists throughout the world.” Ms. Greco also confirmed that Millipore, who, along with their many subsidiaries, are clients, and noted that, “they (Millipore) own the largest group of life science product companies in the world.”
The Process and the Product
The abortion aftermarket industry has come a long over the last ten years. However, raw material requirements remain the same. Aborted fetuses.
The process of product fulfillment begins with the termination of a pregnancy. Women today are not told what happens to the fetus they have aborted. A decade ago the informed consent process at abortion clinics required that the person considering abortion be informed that the fetus could be donated for research. Recent interviews with several abortion clinic representatives revealed that most abortion providers, including Planned Parenthood, no longer address the issue of fetal remains disposition during the pre-abortion “informed consent” counseling. If a patient asks what happens to the fetus after it is aborted, they inform her that “The pregnancy is disposed of in a clinical manner by an outside medical services provider”.
However, none of the clinics contacted would admit to knowing exactly what happens to the fetal tissue once it leaves their facility by courier. A source at the Planned Parenthood clinic in Northwest Washington D.C. did concede that it is “possible that the tissue might be used for research. The waste from a terminated pregnancy becomes the property of the clinic when the woman chooses to abort. They, by default, allow us to dispose of the remains in whatever manner as we choose.” (Obviously this includes the selling for profit of fetal remains).
A representative from Washington Services Clinic voiced that they use the same policy and courier service as Planned Parenthood for all abortions up to 22 weeks, but said, “Any fetus beyond the 22-week stage is cremated.” When questioned further, the woman did admit that the “same courier picks up all the fetuses regardless of term”, and she could not “know with certainty which of the fetuses were cremated.”
The best glimpse into how the back rooms of abortion clinics currently operate came from a doctor who works for Maryland Women’s Health Clinic (Leroy Carhart purchased this clinic from the doctor who owned and operated in 2008 when this interview took place). The doctor detailed to this reporter how he screens the women for drug use and disease, blood type and race. He would not admit to ‘donating’ or ‘selling’ fetuses, but he quite clearly described the process his clinic uses post-abortion:
“We put the fetus along with the umbilical cord and placenta in a heavy gauge red plastic bag provided to us by the company that removes the fetuses. We pour in a solution similar to saline, then seal the bag and refrigerate it. A courier comes in the evening and picks up all the bags from the day’s abortions.”
When asked how the courier transports the bags, the doctor said “I believe he has a cooler of some sort with dry ice in it. I cannot say that he is taking the bags to a research lab, but I do know that at every point we are concerned with preserving the fetus. It could get really nasty, and not very productive, if we just threw them in a tub somewhere.” When asked if the clinic keeps records on all this he said he would not answer any more questions, and then he hung up the phone.
It is obvious that many aborted fetuses end up in research laboratories, where they can be rendered in a variety of ways. The vital organs are separated and packaged, cellular tissue assayed. Skin cells are isolated for use in burn ointment or “living Skin Cell” cream, such as that manufactured by Neocutis Cosmetic Company. The cells are cloned and re-cloned, over and over to create PSP proteins, pluripotent stem cells and a variety of other living cultures. The female fetus’ ovarian tissue might be shipped to either Israel or the Netherlands, where, according to the BBC, the ovarian follicles of second and third trimester female fetuses are used in experimentation for creating human ovum to be used for invitro fertilization for barren women. The tissue from brain, kidneys, liver, and eyes can all be transplanted into the diseased organs of another living human being.
In all, each aborted fetus can be incorporated into over 400 other life science based resources and products and distributed to more than 32 countries. Human fetal remains can become many other things and even be formed into a functional human component or scientifically created being, perhaps even become many other people through ovum harvesting and stem cell cloning; a 21st Century form of man made eternal life.
Sadly, most of the women who receive abortions have no idea what happens to the child that they carried, much less the potential for propagation of their own cells in the commercial marketplace and into other human beings.
In the middle of all this genomic science lies a mystery. Where and/or who is the link between the abortion clinic and the research laboratory or repository? Who facilitates all the contracts between the abortionists and the users of the fetal tissue? Exactly where does the man in the brown van take his orange coolers filled with fetuses bagged in red plastic? How much money is involved in all this?
According to the price list from Open Lines, Inc. in 1999, the brain of an eight week-old fetus sold for $999. Today (2009) Origene, Inc. sells fetal brain cells for $1500. (See graphics). The financial potential for the abortion aftermarket in the 21st century is astronomical. (And as of 2004, Origene sells a human fetal brain for an average price of $3666.)
Supposedly all the trafficking in abortion remains was to have been monitored by the Secretary of the Department of Health and Human Services since March of 2000. However, the records on fetal tissue trafficking are difficult to obtain, and in many cases, they may not exist.
The Courts in several states have received allegations that Planned Parenthood and other clinics have not provided proper documentation regarding contracts for the services and removal of fetal tissue from their facilities, but for the most part, oversight appears to be scant. So as the industry grows and evolves it becomes ever more opaque. The abortion aftermarket at the present is essentially self-governed. And there are those who say that this is tantamount to leaving the fox in charge of the henhouse.
Afterward:This investigation activity was published in a series on my Lipschtik.com an “inside the DC Beltway news blog” in 2008-2009. (according to google at the time, Lipschtik was the third most popular political blog in DC, right behind CNN and MSNBC). Due to attempts on my life I evacuated DC in early 2009, shortly after Obama took office). I lived in Southern Maryland in a secure location under an assumed identity while I stealthily made day trips into the city to complete the research and meet with sources. The full report was made available to all news media and prolife organizations in April of 2009, necessitating me leaving the DC region permanently for my own safety. I stopped reporting for four years, but continued my research on abortion and the industry.
In 2015, Troy Neuman and David Daleiden filmed and released a series of live videos on the baby body parts industry. Subsequent to a civil suit filed by abortion industry organizations in California, the Supreme Court upheld an award of $16 million, requiring those involved with the undercover filming to pay Planned Parenthood this amount for “damages.” Nothing in the reports was found to be libelous or untrue.
I was subsequently hired by Stream.org to report on the abortion aftermarket issue. Below are links to those reports.
Update: As of 2024, OriGene now specializes in biomedical cloning tissue kits. They offer, among other things, a kit to clone human tissue with other biologics. This is a list of the product types of human biologics they distribute. The tissue and DNA products are derived from abortion remains.